TipRanks
Idexx Laboratories (IDXX)
NASDAQ:IDXX
US Market
IDXX
Idexx Laboratories
RESEARCH TOOLSreports
Want to see IDXX full AI Analyst Report?

Idexx Laboratories (IDXX) Stock Forecast & Price Target

2,175 Followers
See the Price Targets and Ratings of:

IDXX Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
6 Buy
4 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Idexx
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IDXX Stock 12 Month Forecast

Average Price Target

$705.25
▲(28.22% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Idexx Laboratories in the last 3 months. The average price target is $705.25 with a high forecast of $805.00 and a low forecast of $627.00. The average price target represents a 28.22% change from the last price of $550.01.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"516":"$516","661":"$661","806":"$806","588.5":"$588.5","733.5":"$733.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":805,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$805.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":705.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$705.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":627,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$627.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[516,588.5,661,733.5,806],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,517.75,539.8461538461538,561.9423076923077,584.0384615384615,606.1346153846154,628.2307692307693,650.3269230769231,672.4230769230769,694.5192307692307,716.6153846153846,738.7115384615385,760.8076923076924,782.9038461538462,{"y":805,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,517.75,532.1730769230769,546.5961538461538,561.0192307692307,575.4423076923077,589.8653846153846,604.2884615384615,618.7115384615385,633.1346153846154,647.5576923076924,661.9807692307693,676.4038461538462,690.8269230769231,{"y":705.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,517.75,526.1538461538462,534.5576923076923,542.9615384615385,551.3653846153846,559.7692307692307,568.1730769230769,576.5769230769231,584.9807692307693,593.3846153846154,601.7884615384615,610.1923076923076,618.5961538461538,{"y":627,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":620.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":629.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":728.97,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":676.53,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":639.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":636.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":564.66,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":567.46,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":566.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":537.58,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":559.07,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":545.16,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":517.75,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$805.00Average Price Target$705.25Lowest Price Target$627.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on IDXX
Andrea Alfonso
UBS
UBS
$670→$627
Hold
14.00%
Upside
Assigned
10/27/26
Idexx Laboratories price target lowered to $627 from $670 at UBSIdexx Laboratories price target lowered to $627 from $670 at UBS
J.P. Morgan Analyst forecast on IDXX
Chris Schott
J.P. Morgan
J.P. Morgan
$775→$750
Buy
36.36%
Upside
Assigned
10/16/26
Idexx Laboratories price target lowered to $750 from $775 at JPMorganIdexx Laboratories price target lowered to $750 from $775 at JPMorgan
Goldman Sachs Analyst forecast on IDXX
Matthew Dellatorre
Goldman Sachs
Goldman Sachs
$740
Buy
34.54%
Upside
Initiated
10/15/26
Idexx Laboratories initiated with a Buy at Goldman SachsIdexx Laboratories initiated with a Buy at Goldman Sachs
KeyBanc Analyst forecast on IDXX
Scott Schoenhaus
KeyBanc
KeyBanc
―
Hold
―
Initiated
10/12/26
Idexx Laboratories initiated with a Sector Weight at KeyBancIdexx Laboratories initiated with a Sector Weight at KeyBanc
William Blair Analyst forecast on IDXX
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
10/02/26
Analysts' Top Healthcare Picks: Regeneron (REGN), Idexx Laboratories (IDXX)
Bank of America Securities Analyst forecast on IDXX
Michael Ryskin
Bank of America Securities
Bank of America Securities
$660→$665
Hold
20.91%
Upside
Reiterated
08/14/26
Idexx: Neutral Stance Maintained as Long-Term Outlook Stays Opaque, Target Price Raised to $665
Stifel Nicolaus Analyst forecast on IDXX
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$675
Buy
22.73%
Upside
Reiterated
08/14/26
Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX)
Barclays Analyst forecast on IDXX
Glen Santangelo
Barclays
Barclays
$710
Buy
29.09%
Upside
Reiterated
08/11/26
Idexx Laboratories (IDXX) Receives a Buy from Barclays
Morgan Stanley Analyst forecast on IDXX
Erin Wright
Morgan Stanley
Morgan Stanley
$805
Buy
46.36%
Upside
Reiterated
08/05/26
Idexx Laboratories (IDXX) Receives a Buy from Morgan Stanley
Citi Analyst forecast on IDXX
Daniel Grosslight
Citi
Citi
$650→$670
Hold
21.82%
Upside
Reiterated
08/05/26
Citi Keeps Their Hold Rating on Idexx Laboratories (IDXX)
Jefferies Analyst forecast on IDXX
Keith Devas
Jefferies
Jefferies
$792
Buy
44.00%
Upside
Reiterated
05/06/26
Idexx Laboratories (IDXX) Receives a Buy from Jefferies
Piper Sandler Analyst forecast on IDXX
David Westenberg
Piper Sandler
Piper Sandler
$775→$750
Hold
36.36%
Upside
Reiterated
02/09/26
Idexx Laboratories price target lowered to $750 from $775 at Piper SandlerIdexx Laboratories price target lowered to $750 from $775 at Piper Sandler
BTIG Analyst forecast on IDXX
Mark Massaro
BTIG
BTIG
$830→$800
Buy
45.45%
Upside
Reiterated
02/03/26
Idexx Laboratories price target lowered to $800 from $830 at BTIGIdexx Laboratories price target lowered to $800 from $830 at BTIG
Leerink Partners Analyst forecast on IDXX
Daniel Clark
Leerink Partners
Leerink Partners
$745→$785
Buy
42.72%
Upside
Reiterated
11/03/25
Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on IDXX
Andrea Alfonso
UBS
UBS
$670→$627
Hold
14.00%
Upside
Assigned
10/27/26
Idexx Laboratories price target lowered to $627 from $670 at UBSIdexx Laboratories price target lowered to $627 from $670 at UBS
J.P. Morgan Analyst forecast on IDXX
Chris Schott
J.P. Morgan
J.P. Morgan
$775→$750
Buy
36.36%
Upside
Assigned
10/16/26
Idexx Laboratories price target lowered to $750 from $775 at JPMorganIdexx Laboratories price target lowered to $750 from $775 at JPMorgan
Goldman Sachs Analyst forecast on IDXX
Matthew Dellatorre
Goldman Sachs
Goldman Sachs
$740
Buy
34.54%
Upside
Initiated
10/15/26
Idexx Laboratories initiated with a Buy at Goldman SachsIdexx Laboratories initiated with a Buy at Goldman Sachs
KeyBanc Analyst forecast on IDXX
Scott Schoenhaus
KeyBanc
KeyBanc
―
Hold
―
Initiated
10/12/26
Idexx Laboratories initiated with a Sector Weight at KeyBancIdexx Laboratories initiated with a Sector Weight at KeyBanc
William Blair Analyst forecast on IDXX
Ryan Daniels
William Blair
William Blair
―
Buy
―
Reiterated
10/02/26
Analysts' Top Healthcare Picks: Regeneron (REGN), Idexx Laboratories (IDXX)
Bank of America Securities Analyst forecast on IDXX
Michael Ryskin
Bank of America Securities
Bank of America Securities
$660→$665
Hold
20.91%
Upside
Reiterated
08/14/26
Idexx: Neutral Stance Maintained as Long-Term Outlook Stays Opaque, Target Price Raised to $665
Stifel Nicolaus Analyst forecast on IDXX
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$675
Buy
22.73%
Upside
Reiterated
08/14/26
Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX)
Barclays Analyst forecast on IDXX
Glen Santangelo
Barclays
Barclays
$710
Buy
29.09%
Upside
Reiterated
08/11/26
Idexx Laboratories (IDXX) Receives a Buy from Barclays
Morgan Stanley Analyst forecast on IDXX
Erin Wright
Morgan Stanley
Morgan Stanley
$805
Buy
46.36%
Upside
Reiterated
08/05/26
Idexx Laboratories (IDXX) Receives a Buy from Morgan Stanley
Citi Analyst forecast on IDXX
Daniel Grosslight
Citi
Citi
$650→$670
Hold
21.82%
Upside
Reiterated
08/05/26
Citi Keeps Their Hold Rating on Idexx Laboratories (IDXX)
Jefferies Analyst forecast on IDXX
Keith Devas
Jefferies
Jefferies
$792
Buy
44.00%
Upside
Reiterated
05/06/26
Idexx Laboratories (IDXX) Receives a Buy from Jefferies
Piper Sandler Analyst forecast on IDXX
David Westenberg
Piper Sandler
Piper Sandler
$775→$750
Hold
36.36%
Upside
Reiterated
02/09/26
Idexx Laboratories price target lowered to $750 from $775 at Piper SandlerIdexx Laboratories price target lowered to $750 from $775 at Piper Sandler
BTIG Analyst forecast on IDXX
Mark Massaro
BTIG
BTIG
$830→$800
Buy
45.45%
Upside
Reiterated
02/03/26
Idexx Laboratories price target lowered to $800 from $830 at BTIGIdexx Laboratories price target lowered to $800 from $830 at BTIG
Leerink Partners Analyst forecast on IDXX
Daniel Clark
Leerink Partners
Leerink Partners
$745→$785
Buy
42.72%
Upside
Reiterated
11/03/25
Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OMCLOmnicell
PVLAPalvella Therapeutics
ZVRAZevra Therapeutics
STOKStoke Therapeutics
AMRXAmneal Pharmaceuticals
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Idexx Laboratories

3 Months
Daniel ClarkLeerink Partners
Success Rate
7/9 ratings generated profit
78%
Average Return
+7.60%
Copying Daniel Clark's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +7.60% per trade.
1 Year
Jonathan BlockStifel Nicolaus
Success Rate
27/36 ratings generated profit
75%
Average Return
+24.85%
Copying Jonathan Block's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +24.85% per trade.
2 Years
Jonathan BlockStifel Nicolaus
Success Rate
26/36 ratings generated profit
72%
Average Return
+54.21%
Copying Jonathan Block's trades and holding each position for 2 Years would result in 72.22% of your transactions generating a profit, with an average return of +54.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDXX Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
5
6
7
7
8
Hold
5
3
5
6
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
9
12
13
14
In the current month, IDXX has received 8 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. IDXX average Analyst price target in the past 3 months is 705.25.
Each month's total comprises the sum of three months' worth of ratings.

IDXX Financial Forecast

IDXX Earnings Forecast

Next quarter’s earnings estimate for IDXX is $3.72 with a range of $3.64 to $3.82. The previous quarter’s EPS was $4.27. IDXX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IDXX has Performed in-line its overall industry.
Next quarter’s earnings estimate for IDXX is $3.72 with a range of $3.64 to $3.82. The previous quarter’s EPS was $4.27. IDXX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IDXX has Performed in-line its overall industry.

IDXX Sales Forecast

Next quarter’s sales forecast for IDXX is $1.19B with a range of $1.18B to $1.21B. The previous quarter’s sales results were $1.22B. IDXX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IDXX has Performed in-line its overall industry.
Next quarter’s sales forecast for IDXX is $1.19B with a range of $1.18B to $1.21B. The previous quarter’s sales results were $1.22B. IDXX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IDXX has Performed in-line its overall industry.

IDXX Stock Forecast FAQ

What is IDXX’s average 12-month price target, according to analysts?
Based on analyst ratings, Idexx Laboratories’s 12-month average price target is 705.25.
    What is IDXX’s upside potential, based on the analysts’ average price target?
    Idexx Laboratories has 28.22% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IDXX a Buy, Sell or Hold?
          Idexx Laboratories has a consensus rating of Moderate Buy which is based on 6 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Idexx Laboratories’s price target?
            The average price target for Idexx Laboratories is 705.25. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $805.00 ,the lowest forecast is $627.00. The average price target represents 28.22% Increase from the current price of $550.01.
              What do analysts say about Idexx Laboratories?
              Idexx Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of IDXX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.